Andrew D. Seidman

Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri et al. · Journal of Clinical Oncology · 2002 · 1.5K citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

José Baselga, Debu Tripathy, John Mendelsohn et al. · Journal of Clinical Oncology · 1996 · 1.4K citations

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

José Baselga, David G. Pfister, Michael R. Cooper et al. · Journal of Clinical Oncology · 2000 · 743 citations

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Andrew D. Seidman, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2008 · 600 citations · Full text

Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification

Andrew D. Seidman, Monica Fornier, Francisco J. Esteva et al. · Journal of Clinical Oncology · 2001 · 548 citations